
Opinion|Videos|January 20, 2025
Mechanism of Action of Teplizumab in Delaying Onset and Progression of Type 1
Panelists discuss how teplizumab binds to T cells and modifies their function to preserve beta cell function, potentially delaying type 1 diabetes onset in at-risk individuals by an average of 2-3 years.
Advertisement
Episodes in this series

Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Patient Care Online
1
Diagnosis of Obstructive Sleep Apnea
2
With Colonoscopy Capacity Limited, We Need More Momentum Behind Noninvasive Home-Based Tests, Says Mark Fendrick, MD
3
Hidradenitis Suppurativa: Recognition, Staging, and Management in Primary Care
4
FDA Clears Prescription Digital Therapeutic LumosityRx for Adults with ADHD
5


















































































































































































































































































